BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 11408505)

  • 1. Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors.
    Lastowska M; Cullinane C; Variend S; Cotterill S; Bown N; O'Neill S; Mazzocco K; Roberts P; Nicholson J; Ellershaw C; Pearson AD; Jackson MS;
    J Clin Oncol; 2001 Jun; 19(12):3080-90. PubMed ID: 11408505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 17q gain in neuroblastoma predicts adverse clinical outcome. U.K. Cancer Cytogenetics Group and the U.K. Children's Cancer Study Group.
    Bown N; Lastowska M; Cotterill S; O'Neill S; Ellershaw C; Roberts P; Lewis I; Pearson AD;
    Med Pediatr Oncol; 2001 Jan; 36(1):14-9. PubMed ID: 11464868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma.
    Bown N; Cotterill S; Lastowska M; O'Neill S; Pearson AD; Plantaz D; Meddeb M; Danglot G; Brinkschmidt C; Christiansen H; Laureys G; Speleman F; Nicholson J; Bernheim A; Betts DR; Vandesompele J; Van Roy N
    N Engl J Med; 1999 Jun; 340(25):1954-61. PubMed ID: 10379019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing histopathological classification with MYCN, 1p36 and 17q status detected by fluorescence in situ hybridisation from 14 untreated primary neuroblastomas in Singapore.
    Yong MH; Hwang WS; Knight LA; Fung W; Chan MY; Seow WT; Chui CH
    Singapore Med J; 2009 Nov; 50(11):1090-4. PubMed ID: 19960166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma.
    Caron H; van Sluis P; de Kraker J; Bökkerink J; Egeler M; Laureys G; Slater R; Westerveld A; Voûte PA; Versteeg R
    N Engl J Med; 1996 Jan; 334(4):225-30. PubMed ID: 8531999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastoma.
    Spitz R; Hero B; Ernestus K; Berthold F
    Clin Cancer Res; 2003 Oct; 9(13):4835-40. PubMed ID: 14581355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome.
    Brinkschmidt C; Christiansen H; Terpe HJ; Simon R; Lampert F; Boecker W; Dockhorn-Dworniczak B
    Med Pediatr Oncol; 2001 Jan; 36(1):11-3. PubMed ID: 11464859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gain of chromosome arm 17q predicts unfavourable outcome in neuroblastoma patients. U.K. Children's Cancer Study Group and the U.K. Cancer Cytogenetics Group.
    Lastowska M; Cotterill S; Pearson AD; Roberts P; McGuckin A; Lewis I; Bown N
    Eur J Cancer; 1997 Sep; 33(10):1627-33. PubMed ID: 9389925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYCN gain and MYCN amplification in a stage 4S neuroblastoma.
    Noguera R; Cañete A; Pellín A; Ruiz A; Tasso M; Navarro S; Castel V; Llombart-Bosch A
    Cancer Genet Cytogenet; 2003 Jan; 140(2):157-61. PubMed ID: 12645655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deletion of chromosome 1p loci and microsatellite instability in neuroblastomas analyzed with short-tandem repeat polymorphisms.
    Martinsson T; Sjöberg RM; Hedborg F; Kogner P
    Cancer Res; 1995 Dec; 55(23):5681-6. PubMed ID: 7585654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYCN amplification and 17q in neuroblastoma: evidence for structural association.
    O'Neill S; Ekstrom L; Lastowska M; Roberts P; Brodeur GM; Kees UR; Schwab M; Bown N
    Genes Chromosomes Cancer; 2001 Jan; 30(1):87-90. PubMed ID: 11107180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
    Spitz R; Hero B; Ernestus K; Berthold F
    Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular analysis of chromosome arm 17q gain in neuroblastoma.
    Janoueix-Lerosey I; Penther D; Thioux M; de Crémoux P; Derré J; Ambros P; Vielh P; Bénard J; Aurias A; Delattre O
    Genes Chromosomes Cancer; 2000 Jul; 28(3):276-84. PubMed ID: 10862033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors.
    Berbegall AP; Villamón E; Piqueras M; Tadeo I; Djos A; Ambros PF; Martinsson T; Ambros IM; Cañete A; Castel V; Navarro S; Noguera R
    Oncogene; 2016 Mar; 35(11):1423-32. PubMed ID: 26119945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gain of chromosome arm 17q is associated with unfavourable prognosis in neuroblastoma, but does not involve mutations in the somatostatin receptor 2(SSTR2) gene at 17q24.
    Abel F; Ejeskär K; Kogner P; Martinsson T
    Br J Cancer; 1999 Dec; 81(8):1402-9. PubMed ID: 10604740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
    Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
    Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological characteristics of neuroblastoma with partial deletion in the short arm of chromosome 1.
    Hiyama E; Hiyama K; Ohtsu K; Yamaoka H; Fukuba I; Matsuura Y; Yokoyama T
    Med Pediatr Oncol; 2001 Jan; 36(1):67-74. PubMed ID: 11464909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromosomes that show partial loss or gain in near-diploid tumors coincide with chromosomes that show whole loss or gain in near-triploid tumors: evidence suggesting the involvement of the same genes in the tumorigenesis of high- and low-risk neuroblastomas.
    Tomioka N; Kobayashi H; Kageyama H; Ohira M; Nakamura Y; Sasaki F; Todo S; Nakagawara A; Kaneko Y
    Genes Chromosomes Cancer; 2003 Feb; 36(2):139-50. PubMed ID: 12508242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
    Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
    Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Numerical and structural aberrations in advanced neuroblastoma tumours by CGH analysis; survival correlates with chromosome 17 status.
    Cunsolo CL; Bicocchi MP; Petti AR; Tonini GP
    Br J Cancer; 2000 Nov; 83(10):1295-300. PubMed ID: 11044353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.